GAITHERSBURG, Md., Oct. 14, 2011 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCBB:CMXI) (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, announced today the execution of a letter agreement granting an undisclosed global pharmaceutical company an exclusivity period until December 31, 2011 to conduct further due diligence regarding the AutoloGel™ System. In exchange, Cytomedix will receive a $2 million non-refundable option fee within 15 days.
